The Just Price of Cancer Drugs

Academic Literature

Pricing in the Market for Anticancer Drugs

What are unique features of the market for anticancer drugs?

Journal of Economic Perspectives 12/01/2015

Academic Literature

The Price Tag on Progress — Chemotherapy for Colorectal Cancer

During the past decade, the Food and Drug Administration (FDA) has approved five new drugs for metastatic colorectal cancer.

New England Journal of Medicine 07/22/2014

Articles

In Cancer Care, Cost Matters

A phenomenally expensive new cancer drug, Zaltrap, was not more clinically effective than existing medicines for colorectal cancer yet it was priced more than twice as high so we refused to offer it.

NYTimes 10/14/2012

Academic Literature

Limits on Medicare's Ability to Control Rising Spending on Cancer…

The growth in spending on cancer drugs can be attributed primarily to a unique legislative and regulatory framework that shields such drugs from the strategies that Medicare typically uses to hold down prices.

NEJM 02/05/2009

Reports

Xeljanz, the FDA, and nine years of patient harm

Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action

Drug Pricing Lab 05/31/2022

Reports

Atypical antipsychotics: Decades of use, unfathomable harms

Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly

Drug Pricing Lab 05/31/2022

Reports

Medicare Part B Premium Dynamics Explained

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Milliman 12/23/2021

Reports

Comparing Factors that Influence Pharmaceutical Pricing and Access in the…

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

Drug Pricing Lab 12/20/2021

Reports

Biosimilars in Medicare Part D: pricing dynamics and considerations

The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.

Milliman 12/14/2021

Reports

Evaluating Industry’s Drug Pricing Claims

A closer look at three of PhRMA’s most cited talking points.

Drug Pricing Lab 11/18/2021

Mapping conflict of interests: scoping review

A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.

Drug Pricing Lab 11/03/2021

Reports

Production Plus Profit Pricing (P-quad) FAQ

08/17/2021